Prior Authorization

AETNA BETTER HEALTH ILLINOIS FAMILY HEALTH PLAN (MEDICAID)

Intron A & Alferon N (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-844-242-0908**.

When conditions are met, we will authorize the coverage of Intron A & Alferon N (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name (please circle)					
INTRON A solution for injection (ir	nterferon alfa-2b) INTRON A powder for solu	ution (inte	erferon alfa-	2b)	
ALFERON N (interferon alfa-n3)	·	,		·	
Other, Please specify:					
Quantity Frequency		Strength			
Route of Administration	Expected Length of therapy				
Patient Information					
Patient Phone:					
Prescribing Physician					
Physician Name:					
Specialty:	NPI Number:				
Physician Fax:	Physician Phone:				
Physician Address:	City, State, Zip:				
Diagnosis:	ICD Code:				
Please circle the appropriate answ					
•	d this medication in the past vious authorization is on file	Y	N		
[If yes, skip to question 2	25.]				
2. Is this request for Alfero	n N?	Υ	N		
[If yes, skip to question :	21.]				
3. Is this request for Intron	A?	Υ	N		

[If no, then no further questions.] 4. Is Intron A prescribed by, or in consultation with an Υ Ν appropriate specialist based on the condition being treated? List specialty: [If no, then no further questions.] 5. Does the patient have a diagnosis of chronic hepatitis Υ Ν B? [If no, skip to question 13.] 6. Was the patient surface antigen positive (HBsAg Υ Ν positive) for more than six months? [If no, no further questions.] 7. Is the patient e-antigen positive (HBeAg positive)? Υ Ν [If no, skip to question 9.] 8. Does the patient have hepatitis B DNA levels greater Υ Ν than or equal to 20,000 IU/mL? [If no, then no further questions.] [If yes, skip to question 10.] 9. Does the patient have hepatitis B DNA levels greater Υ Ν than or equal to 2,000 IU/mL? [If no, then no further questions.] 10. Does the patient have compensated liver disease Υ Ν (e.g., normal bilirubin, albumin, hemoglobin, neutrophils, and platelets)? [If no, then no further questions.] 11. Is there evidence of liver inflammation (e.g., ALT Υ Ν levels elevated to more than 2 times ULN (>2x ULN),

Reference Number: C6637-A/ Effective Date: 02/22/2017

[If no, then no further questions.]

inflammation or fibrosis on liver biopsy)?

12. Is the patient at least 1 year old?	Υ	Ν
[No further questions.]		
13. Does the patient have a diagnosis of AIDS-related Kaposi's sarcoma?	Y	N
[If no, skip to question 16.]		
14. Is Intron A being used for the treatment of visceral AIDS-related Kaposi's sarcoma associated with rapidly progressive disease?	Y	N
[If yes, no further questions.]		
15. Is the request for the powder for solution formulation?	Υ	Ν
[If no, then no further questions.]		
[If yes, skip to question 24.]		
16. Does the patient have a diagnosis of hairy cell leukemia?	Y	N
[If no, skip to question 19.]		
17. Does the patient meet ONE of the following criteria: A) Had less than complete response to cladribine or pentostatin; B) Had disease relapse within 1 year after a complete response to cladribine or pentostatin? 	Y	N
[If no, then no further questions.]		
18. Does the patient have at least ONE of the following: A) Systemic symptoms – fatigue, weakness, weight loss, fever, night sweats; B) Symptomatic splenomegaly or adenopathy; C) Significant cytopenias – hemoglobin less than 12 g/dL, platelet count less than 100,000/mcL, or ANC less than 1500/mcL?	Y	N
[If no, then no further questions.]		
[If yes, skip to question 24.]		
19. Does the patient have a diagnosis of malignant melanoma?	Y	N

	[If no, skip to question 21.]		
20	Has the patient undergone surgical resection AND is at high risk for recurrence (e.g., primary tumor is more than 4 mm thick, presence of ulceration, and/or lymph node involvement)?	Υ	N
	[If no, then no further questions.]		
	[If yes, skip to question 24.]		
21.	Does the patient have a diagnosis of Condylomata acuminate (genital or venereal warts)?	Υ	N
	[If no, then no further questions.]		
22.	Has the patient failed topical treatments or surgical techniques for the same lesion [e.g., cryotherapy, laser removal, surgical excision, electrodessication, imiquimod (Aldara) cream, Podofilox]?	Y	N
	If yes, list treatments tried and dates:		
	[If no, then no further questions.]		
23.	Are the lesion(s) small in size and limited in number and this is prescribed for intralesional use?	Y	N
	[If no, then no further questions.]		
24.	. Is the patient at least 18 years old?	Υ	Ν
	[No further questions.]		
25.	. Is the renewal request for Intron A?	Υ	Ν
	[If no, skip to question 30.]		
26	Is this a renewal request for Intron A for treatment of hepatitis B?	Υ	N
	[If no, skip to question 29.]		
27.	Does the patient continue to be positive for hepatitis B e-antigen (HBeAG +)?	Υ	N
	[If yes, then no further questions.]		

Prescriber (Or Authorized) Signature	Dat	e					
affirm that the information given on this form is true and accurate as of this date.							
Comments:							
33. Has the patient had a response to treatment?	Υ	N					
[If no, then no further questions.]							
32. Does the patient have signs of disease progression?	Y	N					
[If yes, then skip to question 33.]							
31. Are the treatments at least 3 months apart?	Υ	N					
[If no, then no further questions.]							
30. Is this a renewal request for Alferon-N for treatment of genital or venereal warts?	Υ	N					
[No further questions.]							
29. Has the patient had a response to treatment?	Υ	N					
[No further questions.]							
28. Has the patient already received 2 years of treatment with Intron A?	Y	N					